https://allsci.com/news/biotech/ai-protein-models-enzyme-therapy-profluent-taps/ AllScien 2026-10-01T12:54:02.752048Z BioMarin taps Profluent AI models for novel enzyme therapies https://allsci.com/news/biotech/regeneron-sanofi-il-4-il-13-alliance-and-expand/ AllScien 2026-10-01T12:42:56.158554Z Sanofi commits up to USD 8b for Regeneron’s long-acting immunology antibodies https://allsci.com/news/biotech/therapeutics-expands-series-r1-to-805-million-to/ AllScien 2026-10-01T09:51:12.964505Z R1 Therapeutics expands Series A to USD 80.5m as AP306 nears Phase IIb readout https://allsci.com/news/biotech/gsk-wave-spina-sirna-hepatology-selects-waves/ AllScien 2026-10-01T09:16:45.499113Z Wave lands USD 12m as GSK advances SpiNA siRNA program https://allsci.com/news/clinical-trials/eloratzp-obesity-diabetes-trial-lillys/ AllScien 2026-10-01T08:36:39.236239Z Lilly's EloraTZP combination tops tirzepatide alone in Phase IIb obesity and diabetes trial https://allsci.com/news/biotech/thermostable-mrna-vaccines-mit-researchers/ AllScien 2026-09-30T17:57:59.317114Z MIT uses AI to create mRNA vaccines stable for months without ultra-cold storage https://allsci.com/news/clinical-trials/abbv-295-obesity-trial-abbvies-amylin-analog/ AllScien 2026-09-30T17:48:29.746749Z AbbVie’s ABBV-295 supports monthly dosing after Phase I obesity study https://allsci.com/news/business/space-based-drug-manufacturing-varda-raises-usd/ AllScien 2026-09-30T17:29:53.326837Z Varda raises USD 251m Series D to scale space-based drug manufacturing toward orbital medicines https://allsci.com/news/biotech/treatment-resistant-depression-darpa-nrx-secures/ AllScien 2026-09-30T17:07:09.757116Z DARPA awards NRx USD 11.2m to test NRX-101 with rapid robotic TMS in depression https://allsci.com/news/clinical-trials/ebglyss-atopic-dermatitis-trial-lillys-wins-phase/ AllScien 2026-09-30T16:44:59.240111Z Lilly's Ebglyss wins Phase IIIb trial in hand and foot atopic dermatitis, seeks label expansion https://allsci.com/news/clinical-trials/trappsol-cyclo-npc-trial-rafaels-misses-primary/ AllScien 2026-09-30T14:59:01.059053Z Rafael’s Trappsol Cyclo misses Phase III primary endpoint but shows subgroup benefit https://allsci.com/news/licensing-and-partnerships/ai-drug-discovery-platform-cas-and-novartis/ AllScien 2026-09-30T14:22:20.311786Z Novartis and CAS build reaction-data backbone for AI drug discovery https://allsci.com/news/biotech/barda-funding-antifungal-awards-scynexis-up-to/ AllScien 2026-09-30T14:05:10.461054Z Scynexis secures up to USD 214m in BARDA funding for antifungal SCY-247 https://allsci.com/news/clinical-trials/retatrutide-weight-loss-diabetes-lillys-achieves/ AllScien 2026-09-30T12:24:26.614108Z Lilly’s retatrutide delivers 20.8% weight loss in Phase III diabetes-obesity trial https://allsci.com/news/clinical-trials/tasimelteon-delayed-sleep-wake-phase-disorder/ AllScien 2026-09-30T12:13:56.338062Z Vanda’s tasimelteon advances sleep timing in Phase III delayed sleep-wake disorder trial https://allsci.com/news/biotech/vvd-214-colorectal-cancer-msi-high-achieves/ AllScien 2026-09-30T11:13:04.392957Z Vividion’s WRN inhibitor shows first clinical proof of synthetic lethality in MSI-high cancers https://allsci.com/news/biotech/fenebrutinib-fda-approval-ms-accepts-roches/ AllScien 2026-09-30T10:54:54.090984Z Roche’s fenebrutinib gets FDA priority review for RMS and PPMS https://allsci.com/news/biotech/anacardio-series-b-funding-heart-failure/ AllScien 2026-09-30T09:52:19.997567Z AnaCardio raises EUR 62.5m to push ghrelin agonist AC01 toward Phase III https://allsci.com/news/biotech/tau-inhibitors-alzheimers-disease-jillion/ AllScien 2026-09-30T09:28:50.613729Z NIH backs Jillion’s oral small-molecule tau program with USD 1.12m award https://allsci.com/news/venture-financing/rna-therapeutics-funding-4bio-capital-leads-eur/ AllScien 2026-09-30T09:07:19.628187Z 4BIO Capital leads EUR 40m seed round for Aptadir's gene-reactivating RNA platform https://allsci.com/news/biotech/immix-biopharma-funding-car-t-raises-usd-125m-to/ AllScien 2026-09-30T09:00:35.536007Z Immix Bio offering to raise USD 125m after 89% CR rate for BCMA CAR T in amyloidosis https://allsci.com/news/biotech/allogeneic-car-t-cell-rejection-ut-md-anderson/ AllScien 2026-09-30T08:40:56.360501Z MD Anderson study identifies two mechanisms shaping allogeneic CAR T success https://allsci.com/news/biotech/ai3bio-series-a-funding-th17-launches-with-usd/ AllScien 2026-09-29T17:00:37.391504Z ai3Bio launches with USD 48m in Series A funding for Th17 cell targeting therapies https://allsci.com/news/corporate-strategy/ai-health-lab-ortet-launches-as-frontier-with-usd/ AllScien 2026-09-29T16:50:11.632687Z Ortet launches as frontier AI health lab with USD 500m commitment from Thoreau https://allsci.com/news/biotech/savolitinib-fda-approval-astrazeneca-seeks-for/ AllScien 2026-09-29T16:41:32.389845Z AstraZeneca seeks FDA approval for HutchMed's Orpathys plus Tagrisso in MET-driven lung cancer https://allsci.com/news/biotech/kras-egfr-conjugate-therapy-hutchmed-launches/ AllScien 2026-09-29T15:52:36.104674Z HutchMed puts GSK-partnered KRAS-EGFR conjugate into Phase I in China https://allsci.com/news/biotech/diabetic-retinopathy-treatment-funding-breye/ AllScien 2026-09-29T15:20:13.061246Z Novo Holdings co-leads EUR 67.5m Breye Series A for danegaptide Phase II https://allsci.com/news/licensing-and-partnerships/glp-1-gip-agonist-oral-novo-nordisk-licenses/ AllScien 2026-09-29T14:15:57.365185Z Novo puts up USD 300m for Hengrui's Phase I once-weekly oral GLP-1/GIP agonist https://allsci.com/news/biotech/astrazeneca-summit-investment-ivonescimab/ AllScien 2026-09-29T14:02:00.727605Z AstraZeneca invests USD 2b in Summit to advance ivonescimab-ADC combination trials https://allsci.com/news/biotech/hpk1-protac-degrader-arvinas-enters/ AllScien 2026-09-29T13:09:25.497640Z Arvinas enters immuno-oncology with HPK1 PROTAC degrader in Phase I/II trial https://allsci.com/news/biotech/zenkuda-aflibercept-wamd-achieves-non-inferiority/ AllScien 2026-09-29T13:01:19.450121Z Kodiak’s Zenkuda and tabirafusp-ted meet Phase III endpoints in wet AMD